Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of DA414 in Healthy Subjects
NCT06525168Phase 1Recruiting
- Sponsor
- Chengdu Diao Jiuhong Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing DA414 Granules with DA414 Placebo (2 arms). Primary endpoint: Safety and Tolerability. Started Feb 2024; status: recruiting.
02
Drugs
DA414
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06525168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525168.